Myopia Profile

Myopia Action Month now on offering FREE seminars, courses, resources and more: Get involved here.

Myopia Action Month now on: Get involved here.


OSO 2018 - Part 1

Posted on March 25th 2019 by Kate Gifford

In this article:

Discover the highlights from the biennial Orthokeratology Society of Oceania conference covering OrthoK and myopia control research and practice.

The biennial Orthokeratology Society of Oceania (OSO) conference was held in October 2018 at the Gold Coast, Australia. A highlight of the Aussie and NZ contact lens practitioners' educational calendars, OSO is now attracting an international following and boasted an amazing program covering the latest in OrthoK and myopia control research and practice. Pictured above is long serving OSO President Dr Gavin Boneham opening the conference, and a shot of the light fittings which seemed topically appropriate - do they look a bit like a bullseye topography map to you as they do to me?Here are a handful of summaries I posted to the Myopia Profile Facebook page during the conference under #OSO2018.

1 - Animal models of defocus and myopia

Professor Earl Smith (University of Houston, Texas USA) opened the OSO 2018 program with a fascinating summary of the animal model research on visual development and defocus. While studies in baby animals sometimes translate to similar results in small humans, and sometimes don’t, Earl provided fascinating insights into mechanisms of our simultaneous competing optical treatments such as OrthoK, multifocal / dual focus contact lenses and even spectacle lens designs. Three important points which Earl made:

  1. Refractive development is regulated by multiple, independent, local retinal mechanisms which don’t need to leave the eye. Peripheral signals can dominate central, likely because of spatial summation - there’s so much more peripheral retina by surface area. But Earl also said “when I say periphery, I don’t specify where it is because we don’t yet know where the sweet spot is.
  2. The two signals in simultaneous competing defocus treatments don’t seem to lead to ‘averaging’ of the two powers - refractive development appears to be dominated by the most positive powered portion of the lens (more myopic defocus). This is good news for our defocus treatments, although my addition to this is that accommodation in humans could also influence where these defocus zones fall on the retina (Faria-Ribeiro et al, OPO 2018). I don’t know anything about monkey accommodation but they probably don’t have the same near demands as small humans.
  3. Trialing various powers in primate studies indicates that treatment results don’t seem to be graded - as long as a signal reaches a given strength, maximal treatment effects are likely. If treatment results appear to be all-or-none in primates, in small human primates this could mean that maybe we don’t need more peripheral plus for more myopia control. We just need to reach a threshold. But we don’t know yet what the threshold is and if it’s an individualised thing.

2 - Quality of life and number needed to treat in OK

Assistant Professor Michael Lipson (from University of Michigan, USA) discussed the latest in OrthoK. Before his lecture we had a chat about the strong uptake of OK in Australia and NZ compared to what he sees in the US. Why is this? I think we’ve benefited from the OSO holding these amazing conferences for nearly 20 years, to share the leading research being done in Australia by the UNSW Research in Orthokeratology (ROK) group led by Professor Helen Swarbrick and by cutting edge clinician-scientists like John Mountford. The core group of OK fitters in Australia has grown a lot in the past few years as myopia control awareness has grown. Anyway, back to Michael’s lecture!

  1. Quality of life in OK wear is superior to SCL wear - in a crossover study undertaken by Michael and colleagues, with two month wearing periods of each modality, they found that 70% preferred to continue with OK and for patients under 3D of myopia, this was 90%. Myopia control aside, patients love it!
  2. Number needed to treat (NNT) - treating only TWO young myopes with OK will reduce risk of developing high myopia. By comparison, the NNT to prevent one person with ocular hypertension from developing glaucoma is 20, and 50 people need to take statins to prevent one person suffering a cardiovascular event!

3 - When to use a toric OK lens

Dr Vinod Masseedupally from the Research in Orthokeratology (ROK) group (University of New South Wales, Australia) investigated astigmatism and lens centration in his PhD. He found that a corneal elevation difference (CED) of more than 30 microns led to increased decentration of the central treatment zone. Once a toric lens was fit to these higher CED eyes, the centration was like a spherical lens on a spherical cornea again. Future work will investigate the effect of types of corneal toricity (central or limbus-to-limbus) on lens centration. Vinod's earlier work on OK decentration in toric vs spherical corneas can be found here.

Read OSO2018 Part 2 here.

Meet the Authors:

About Kate Gifford

Dr Kate Gifford is a clinical optometrist, researcher, peer educator and professional leader from Brisbane, Australia, and a co-founder of Myopia Profile.

Back to all articles

Enormous thanks to our visionary sponsors

Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.